NCT01215981

Influenza Vaccine Post Allogeneic Transplant

MT2010-08R Influenza Vaccine Specific Immune Responses After Allogeneic Hematopoietic Cell Transplantation: Are One or Two Vaccine Doses Needed?

• Status: Terminated
• Phase: N/A
• Study type: Interventional
• Enrollment: 68 (actual)
• Sponsor: Masonic Cancer Center, University of Minnesota · Academic / Other
• Sex: All
• Age: 6 Months
• Healthy volunteers: Accepted

Summary

Study Design: This is a randomized, single center study to evaluate immune responses to the seasonal influenza vaccine in allogeneic hematopoietic stem cell transplant (HSCT) recipients who receive one vaccine or two vaccine doses one month apart. In addition, a cohort of healthy adult volunteers will be recruited as controls to confirm immune response to a single influenza vaccine.

Conditions

• Hematopoietic Stem Cell Transplant
• Hematologic Malignancy

Interventions

Type	Name	Description
BIOLOGICAL	Influenza vaccine	One dose of inactivated hemagglutinins of influenza A (H1N1, H3N2) and influenza B
BIOLOGICAL	Influenza vaccine	Two doses of inactivated hemagglutinins of influenza A (H1N1, H3N2) and influenza B

Timeline

• Start date: 2010-09-01
• Primary completion: 2011-06-01
• Completion: 2011-06-01
• First posted: 2010-10-07
• Last updated: 2017-12-28
• Results posted: 2016-08-16

Locations

1 site across 1 country: United States